Roles of noncoding RNAs in drug resistance in multiple myeloma. Issue 11 (23rd April 2020)

• Record Type: Journal Article
• Authors: Li, Jingwen; Zou, Jing; Wan, Xiaoyue; Sun, Chunyan; Chu, Zhangbo; Hu, Yu
• Is Part Of: Journal of cellular physiology. Volume 235:Issue 11(2020:Nov.)
• Page Start: 7681
• Page End: 7695
• Publication Date: 2020-04-23
• Subjects: drug resistance -- long noncoding RNA -- microRNA -- multiple myeloma -- signaling pathway; Physiology -- Periodicals; Cell physiology -- Periodicals; 571.6
• DOI: 10.1002/jcp.29726
• Languages: English
• ISSNs: 0021-9541

Abstract

Abstract: Despite the administration of new effective drugs in recent years, relapse and drug resistance are still the main obstacles in multiple myeloma (MM) treatment, making MM an incurable disease. To overcome drug resistance in MM, it is critical to understand the underlying mechanisms of malfunctioning gene expression and develop novel targeted therapies. During the past few decades, with the discovery and characterization of noncoding RNAs (ncRNAs), the landscape of dysregulated ncRNAs of cancers as well as their biological and pathobiological functions in tumorigenesis and drug resistance have been recognized. Studies about ncRNAs improved the understanding of variations of drug response among individuals at a level distinguished from genetic polymorphism, and provided with new orientations for targeted therapies. In this review, we will summarize the emerging impact and underlying molecular mechanisms of the most relevant classes of ncRNAs in drug resistance of MM, and discuss the potential as well as strategies of treating ncRNAs as therapeutic targets. Abstract : This review summarized the role of noncoding RNAs (ncRNAs) including microRNA (miRNA), long noncoding RNA (lncRNA), and circular RNA (circRNA) in drug resistance in multiple myeloma (MM) and discussed the underlying molecular mechanisms, and finally provided with an overview of the potential and strategies of treating ncRNAs as therapeutic targets.